Oakbrook Investments Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Oakbrook Investments reduced its stake in Amgen by 10.56% during the most recent quarter end. The investment management company now holds a total of 207,688 shares of Amgen which is valued at $33,257,079 after selling 24,525 shares in Amgen , the firm said in a disclosure report filed with the SEC on Apr 14, 2016.Amgen makes up approximately 2.12% of Oakbrook Investments’s portfolio.

Amgen opened for trading at $159.49 and hit $162.1 on the upside on Monday, eventually ending the session at $161.7, with a gain of 0.98% or 1.57 points. The heightened volatility saw the trading volume jump to 20,81,057 shares. Company has a market cap of $121,613 M.

Other Hedge Funds, Including , Capital Asset Advisory Services boosted its stake in AMGN in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 2,459 shares of Amgen which is valued at $393,760. Amgen makes up approx 0.45% of Capital Asset Advisory Services’s portfolio.Exchange Capital Management reduced its stake in AMGN by selling 95 shares or 0.41% in the most recent quarter. The Hedge Fund company now holds 22,842 shares of AMGN which is valued at $3,657,689. Amgen makes up approx 1.56% of Exchange Capital Management’s portfolio.Central Trust Co reduced its stake in AMGN by selling 53 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 48,745 shares of AMGN which is valued at $7,805,537. Amgen makes up approx 0.61% of Central Trust Co’s portfolio.West Oak Capital reduced its stake in AMGN by selling 45 shares or 0.44% in the most recent quarter. The Hedge Fund company now holds 10,082 shares of AMGN which is valued at $1,576,724. Amgen makes up approx 1.23% of West Oak Capital’s portfolio.

On the company’s financial health, Amgen reported $2.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.29. The company had revenue of $5536.00 million for the quarter, compared to analysts expectations of $5534.94 million. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 EPS.

Investors should note that on Mar 2, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced May 13, 2016 as the ex-dividend date and fixed the record date on May 17, 2016. The payable date has been fixed on Jun 8, 2016.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.Shares were Reiterated by Argus on Feb 8, 2016 to “Buy” and Lowered the Price Target to $ 185 from a previous price target of $202 .Credit Suisse Initiated Amgen on Jan 20, 2016 to “Outperform”, Price Target of the shares are set at $205.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.